Ternary Therapeutics Secures Seed Funding
Ternary Therapeutics, a biotechnology startup based in London, has raised £3.6 million in a seed funding round dated March 16, 2026. The company is working on revolutionizing the field of Molecular Glue Discovery by integrating advanced Machine Learning techniques with Molecular Dynamics simulations and AI-augmented drug discovery.
Details of the Funding Round
The seed round was led by the European venture firm daphni, with additional participation from Pace Ventures, the i&i Biotech Fund, and the UK Innovation & Science Seed Fund. This infusion of capital will enable Ternary Therapeutics to further develop its AI platform designed to create molecular glues—medicines aimed at targeting proteins that have traditionally been considered undruggable.
Company Background and Technology
Founded in 2024, Ternary Therapeutics aims to address the challenges associated with drug discovery. The company's platform combines machine learning and physics-based molecular modeling to predict protein behaviors and identify potential molecules that can facilitate protein-protein interactions. These predictions are then tested in the lab, and the results are used to refine the models, making the drug discovery process more efficient and predictable.
Chris Tame, the Founder and CEO, emphasized the significance of their approach by saying, "Our platform is designed to change that by combining physics-informed AI with rapid experimental validation to engineer these molecules intentionally and at scale."
Strategic Plans for the New Funding
The newly acquired funds will be used to scale Ternary's platform and accelerate the development of molecular glue therapeutics. The company plans to expand its team and enhance its pipeline of programs, especially focusing on treatments for inflammatory and neuroinflammatory diseases. Additionally, Ternary Therapeutics has appointed Dr. Ian Taylor to its board of directors, bringing in his expertise in targeted protein degradation research.
Conclusion
With this significant financial backing, Ternary Therapeutics is poised to make substantial advancements in the drug discovery sector. By leveraging cutting-edge AI and machine learning technologies, the company aims to transform the development of molecular glues from a serendipitous process into a systematic engineering challenge, potentially paving the way for new treatments for diseases that are currently hard to target with conventional drugs.